Domestic brokerage Bajaj Broking has issued a Buy call on Sun Pharmaceutical Industries, setting a target price of Rs 2,180 in its High Conviction Margin Trading Funding pick dated July 28, 2026. The recommendation comes as shares of India's largest drugmaker trade near record highs, having advanced 13.5% so far in the current fiscal year, comfortably ahead of the Nifty 50's 8% gain over the same stretch. Analysts at the brokerage point to a decisive technical breakout, a faster-than-usual retracement of the stock's prior decline, and a supportive momentum reading on the monthly chart as the basis for their bullish stance. The target implies roughly 11% upside from current levels, with a clearly defined support zone for investors tracking downside risk.

Brokerage Backs a Breakout

Sun Pharma shares slipped 0.5% to Rs 1,965 on Wednesday even as the broader Nifty 50 climbed 1% and the Nifty Pharma index added 0.5%, a modest pause in what Bajaj Broking describes as a decisive structural shift. The brokerage's research note, dated July 28, 2026, flags a breakout above the stock's 21-month consolidation range of Rs 1,583 to Rs 1,960 — a technical development analysts say opens a fresh entry window for investors who missed the earlier leg of the rally.

A Faster Recovery Than the Decline

What stands out to the brokerage is the pace of the reversal. Sun Pharma spent 16 months sliding from Rs 1,960 to Rs 1,583, but has clawed back that entire decline in just five months. Bajaj Broking's note characterizes this asymmetry as a signal of "robust demand and a decisive shift in momentum," arguing that such compressed retracements typically precede sustained trend continuation rather than a temporary bounce.

Reading the Structural Trend

Beyond the breakout itself, analysts point to a broader structural change. The stock has cleared a major multi-month consolidation zone, a pattern technicians generally interpret as the formation of a new, higher base from which further gains can be built. Bajaj Broking's note states plainly that this "points towards a continuation of the primary uptrend and underscores the stock's long-term bullish structure."

Higher Highs, Higher Lows

Chart watchers at the brokerage also cite a textbook uptrend signature: a sequence of higher highs and higher lows stretching across recent months. This pattern, considered one of the more reliable trend-confirmation tools in technical analysis, reinforces the brokerage's conviction that the current move has structural underpinning rather than being a short-lived spike.

Momentum Indicators Turn Supportive

The fourth pillar of Bajaj Broking's bullish case rests on momentum. The monthly 14-period Relative Strength Index has moved into an uptrend, recently crossing above its 9-period average — a classic buy signal among technical traders. The brokerage notes this crossover adds weight to the broader bullish structure already visible on the price chart.

Key Levels for Investors to Track

What Could Go Wrong

Technical setups can and do fail. A sustained close below the Rs 1,860 support would undercut the bullish thesis Bajaj Broking has laid out. Investors should also weigh sector-wide pressures that sit outside pure chart analysis: continued pricing pressure in the US generics market and periodic FDA compliance scrutiny at Indian manufacturing facilities have both weighed on pharma stocks in the past and could resurface as headwinds regardless of technical positioning.

The Bottom Line

Bajaj Broking's call rests on technical evidence, not a fresh reading of Sun Pharma's earnings or valuation. Investors should treat the Rs 2,180 target as a chart-based projection, best considered alongside the company's fundamentals and sector outlook rather than as a standalone reason to buy. As always with brokerage research, the views belong to the research house issuing them and should not be read as a guarantee of returns.

Views and price targets belong to Bajaj Broking and are not endorsed by TopNews. This article is for informational purposes only and does not constitute investment advice. Readers are advised to consult a SEBI-registered financial advisor before making investment decisions.